Voyager reports Q4 2022 net loss of $23.6M; highlights partnerships with Neurocrine, Novartis, Pfizer

Voyager Therapeutics, Inc.

Q4 2022 net loss $23.6M vs $5.7M income in Q4 2021; full-year net loss $46.4M vs $71.2M loss in 2021.
Neurocrine collaboration closed Jan 2023: $175M upfront, up to $4.2B milestones, plus royalties and opt-in for GBA1 program.
Novartis exercised capsid license options for two CNS targets (March 2023): $25M payment, up to $600M milestones plus royalties.
Pfizer exercised capsid option in Oct 2022: $10M payment, up to $290M milestones plus royalties.
Cash $118.8M at Dec 31, 2022; expected into 2025 after deals. Pipeline: VY-TAU01 selected, SOD1 candidate in H1 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.